bioAffinity Technologies reports skin cancer siRNA preclinical results
Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.


_1425871_640x360_2504341059893-640x360.webp&w=3840&q=75)


_1425855_640x360_2504343619538-640x360.webp&w=3840&q=75)





